Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
Sponsor: University of Michigan Rogel Cancer Center • ClinicalTrials.gov ID: NCT07526545
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.
Interventions
-
Biopsy Procedure
(Procedure)
Undergo biopsy
-
Diagnostic Procedure
(Device)
Undergo MPS2 urine test
-
Electronic Health Record Review
(Other)
Ancillary studies
-
Magnetic Resonance Imaging
(Procedure)
Undergo MRI
Eligibility criteria
Conditions
Locations
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record